Data Supporting Drug Price Hikes Deemed Faulty

By Karen Blum
The Institute for Clinical and Economic Review (ICER) rejects nearly all (97%) evidence submitted by manufacturers when preparing its annual Unsupported Price Increase (UPI) reports, according to a new analysis.